A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 234-239

  Jatoi, Aminah ^a   Ritter, Howard L ^b   Dueck, Amylou ^a   Nguyen, Phuong L ^a   Nikcevich, Daniel A ^c   Luyun, Ronnie F ^d   Mattar, Bassam I ^e   Loprinzi, Charles L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b Toledo Community Hospital Oncology Program   (United States)

^c Carle Cancer Center CCOP ^*  (United States)

^d Carle Cancer Center CCOP   (United States)

^e WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

Author keywords

Cancer associated weight loss; Double blind trial; Elderly patients; Infliximab; Non small cell lung cancer

Indexed keywords

DOCETAXEL; GENOMIC DNA; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; AGE; AGED; ANEMIA; APPETITE; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICAL PERFORMANCE; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; POLYMORPHISM, GENETIC; QUALITY OF LIFE; TAXOIDS; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 77950459905     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.020     Document Type: Article

References (13)

1. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980, 69:491-497.
2. Rolland Y., Czerwinski S., Abellan Van Kan G., Morley J.E., Cesari M., Onder H., et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008, 12:433-450.
3. Mateen F., Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr 2006, 25:711-715.
4. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., Krook J.E., Wilwerding M.B., et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999, 17:3299-3306.
5. Figueras M., Busquets S., Carbo N., Almendro V., Argiles J.M., Lopez-Soriano F.J. Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int J Oncol 2005, 27:855-860.
6. Argiles J.M., Busquets S., Lopez-Soriano F.J. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003, 6:401-406.
7. Torelli G.F., Meguid M.M., Moldawer L.L., Edwards C.K., Kim H.J., Carter J.L., et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 1999, 277:R850-R855.
8. Sloan J.A., Loprinzi C.L., Laurine J.A., Novotny P.J., Vargas-Chanes D., Krook J.E., et al. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol 2001, 19:3539-3546.
9. Jatoi A., Jett J.R., Sloan J., Novotny P., Ford J., Prabhakar U., et al. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer 2004, 12:859-863.
10. Lipsky P.E., van der Heijde D.M., St.Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602.
11. Wiedenmann B., Malfertheiner P., Friess H., Ritch P., Arseneau J., Mantovani G., et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008, 6:18-25.
12. Jatoi A., Dakhil S.R., Nguyen P.L., Sloan J.A., Kugler J.W., Rowland K.M., et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007, 110:1396-1403.
13. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008, 121:S21-S31.